14 October 2014

Highlights in Medicinal Chemistry

Organised by:

 SCI’s Fine Chemicals Group

SCI, London, UK

Registration Closed

This event is no longer available for registration.

Synopsis
This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.
Attendees

This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.


Programme

Day 1

09:20
Registration and refreshments
09:50
Welcome and introduction
09:55
Data mining ChEMBL for new leads against new targets
Dr John Overington, European Molecular Biology Laboratory - European Bioinformatics Institute (EMBL-EBI)
10:35
Fatty Acid Synthase (FAS) triazolone inhibitors, good potency & properties but a metabolic liability?
Dr Cliff Jones, AstraZeneca
11:00
Stabilised receptor enabled structure based drug design: Identification of dual orexin receptor antagonists (DORAs)
Dr Sarah Aves, Heptares
11:25
Refreshments
11:45
Squaramides: physical properties, synthesis & application in medicinal chemistry
Dr Ian Storer, Pfizer
12:10
Fragment-based drug discovery for a protein-protein interaction target: from mM fragments to nM dual antagonist of XIAP and cIAP1
Dr Emiliano Tamanini, Astex
12:35
The monster mas agonist - revealing the beauty in the beast
Dr Simon Peace, GlaxoSmithKline
13:00
Lunch and exhibition
14:00
A tale of two MEK inhibitors - the difficulty of preclinical differentiation
Dr Henrik Moebitz, Novartis
14:25
Structure-guided design of BH3-mimetic Mcl-1 inhibitors
Dr Jonathan Hollick, Evotec
14:50
Dr Lilian Alcaraz, Argenta
15:30
Refreshments
15:50
Designing membrane permeable 'large' molecule NS5A inhibitors
Dr David Pryde, Pfizer
16:15
Discovery of ATR selective inhibitors for the treatment of cancer
Dr Joanne Pinder, Vertex
16:40
Matched triplicates in the optimisation of a novel series of glucokinase activators
Dr Mike Waring, AstraZeneca
17:20
Closing remarks
17:25
Wine reception

Venue and Contact

SCI

14/15 Belgrave Square
London SW1X 8PS

 

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Fees

Early Bird Rate - before 29 August 2014

One-Day Fee Two-Day Fee*
SCI Member GB£100 SCI Member GB£175
SCI Student Member GB£35 SCI Student Member GB£60
Non-Member GB£130 Non-Member GB£235

Standard Rate - after 29 August 2014

One-Day Fee Two-Day Fee*
SCI Member GB£115 SCI Member GB£205
SCI Student Member GB£40 SCI Student Member GB£70
Non-Member GB£150 Non-Member GB£270

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Sponsors

Third Tier Sponsor/Exhibitors